Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: EPFL; CHUV.
Données de projet
Numéro du projet: GRS-077/20
Subside accordé: CHF 150'000
Durée: 02.2021 - 07.2022
InnoBooster, seit 2018
Direction du projet
Loulia Kassem, CEO
Chemin des Triaudes 20
1024 Ecublens VD (Schweiz)
Description du projet
Preterm birth (PTB) is one of the main challenges in healthcare; it is the first cause of death of infants, while survivors face high chances of disability. Today, doctors have few ways to identify women at risk of premature birth; they are patients with either symptoms of delivery or a high-risk profile (such as previous preterm birth, short cervix, > 35 years of age, IVF pregnancies). However, half of the women who deliver prematurely fulfil NONE of these conditions. Such women are left with an undetected risk of preterm birth and thus higher chances of neonatal morbidity and mortality. Our mission is to identify all women at risk of a premature birth so that all babies live up to their full potential!
Quelles sont les particularités de ce projet?
Rea develops a first of its kind diagnostic test, accessible for ALL pregnant women to frequently self-test their risk of a preterm birth with the latest technology. Rea's Smart Pad analyzes vaginal secretions of pregnant women for proteins indicative of birth and sends the test results to Rea's phone app.
Rea’s non-invasive technology would decrease the rates of preterm birth by allowing early detection; it would help doctors identify patients for medical interventions to delay delivery and to help mature the organs of the baby. Such early detection of preterm birth helps doctors prepare for optimal neonatal care and potentially decrease the time spent in the incubator, resulting in huge cost savings.
The InnoBooster grant will allow us to test the Smart Pad on pregnant women for the first time and will thus accelerate our market entry.
Performed clinical patient-tests of Rea’s In-Vitro-Diagnostic component.
Obtained regulatory roadmap for Smart Pad.
Recruited a total of 8 FTEs as of January 2022.
Personnes participant au projet
Dernière mise à jour de cette présentation du projet 17.03.2022